Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06213831 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
A Phase 1 study of Prurigo Nodularis, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 20
- Study locations
NCT06213831 is a Phase 1 study of Prurigo Nodularis that has completed, run by Incyte Corporation. The registered enrollment target is 23 participants, below the 228-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06213831, a Phase 1 study of Prurigo Nodularis, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).
Conditions Studied
Interventions
- DRUG Ruxolitinib Cream 1.5%
Study Locations (20)
California
- First Oc Dermatology - Fountain Valley
- Amicis Research Center Valencia - Northridge
- Clinical Science Institute Clinical Research Specialists Inc - Santa Monica
Florida
- Advanced Pharma Cr, Llc - Miami
- Sullivan Dermatology North Miami Beach Office - North Miami Beach
- Olympian Clinical Research - Tampa
Arizona
- Saguaro Dermatology - Phoenix
- Affiliated Dermatology - Scottsdale
Michigan
- Oakland Hills Dermatology Pc - Auburn Hills
- Revival Research Institute, Llc Troy - Troy
Texas
- Dermresearch, Inc. - Austin
- North Texas Center For Clinical Research Ntccr - Frisco
Idaho
- St Lukes Clinic Dermatology Ketchum - Ketchum
Indiana
- Dawes Fretzin Clinical Research Group Llc - Indianapolis
Kentucky
- Equity Medical - Bowling Green
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2024-02-27 |
| Est. Completion | 2025-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06213831
The ClinicalTrials.gov registry entry for NCT06213831 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (90% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib Cream 1.5% is the first listed.
NCT06213831 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06213831 about?
NCT06213831 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream". This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).
What is the current status of trial NCT06213831?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2024-02-27. Estimated completion is 2025-07-17.
What conditions does trial NCT06213831 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT06213831?
The interventions under investigation include: Ruxolitinib Cream 1.5% (DRUG).
Who is sponsoring clinical trial NCT06213831?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06213831 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Idaho, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
Upadacitinib for Prurigo Nodularis
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
RECRUITING · Phase 3
-
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
RECRUITING
-
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.